[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 27, 1941


JAMA. 1941;117(26):2238-2239. doi:10.1001/jama.1941.02820520034008

Erysipelas, a common bacterial infection of the skin caused by the hemolytic streptococcus, is a disease entity particularly suitable for the trial of new chemotherapeutic agents. This is true because the location of the lesion makes it available for accurate study and because methods of treatment prior to the use of sulfanilamide were notably unsatisfactory.1 In 1936, shortly after the introduction of the sulfonamide drugs, Meyer-Heine and Huguenin2 reported 150 cases of erysipelas treated with sulfanilamide producing a rapid fall in the temperature and subsidence of the local lesion within forty-eight hours. There were no deaths and few complications. Breen and Taylor3 in 1937 obtained equally gratifying results in 35 cases treated. There were two deaths in this series. Subsequent publications by Snodgrass and Anderson,4 Hageman and Blake,5 Nelson, Rinzler and Kelsey6 and Hoyne, Wolf and Prim7 state that the sulfonamide drugs are